Holdsworth House Medical Practice
13
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.7%
1 terminated/withdrawn out of 13 trials
90.9%
+4.4% vs industry average
8%
1 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
Role: lead
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
Role: collaborator
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
Role: lead
Patients Empowered With Digital Scripts: ScalaMed
Role: lead
Performance and Usability Evaluation of the Atomo HIV Self-Test
Role: lead
Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia
Role: lead
RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice
Role: lead
Patient Retention in HIV Medical Care in a Primary Care Practice in Australia
Role: lead
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
Role: collaborator
Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months
Role: lead
Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia
Role: lead
Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes
Role: lead
The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
Role: lead
All 13 trials loaded